Profile
Judith Segall is the founder of Lineage Cell Therapeutics, Inc. which was founded in 1990.
She held the title of Vice President-Administration from 2016 to 2019.
Currently, she is the Secretary & Director-Administration at AgeX Therapeutics, Inc. since 2017.
Ms. Segall has also worked as Secretary & Director at Asterias Biotherapeutics, Inc. and as Secretary at OncoCyte Corp.
Ms. Segall received her undergraduate degree from the University of California, Berkeley in 1989.
Former positions of Judith Segall
| Companies | Position | End |
|---|---|---|
| LINEAGE CELL THERAPEUTICS, INC. | Founder | 01/08/2019 |
| AGEX THERAPEUTICS, INC. | Chief Administrative Officer | - |
| ONCOCYTE CORPORATION | Corporate Secretary | - |
| ASTERIAS BIOTHERAPEUTICS INC | Director/Board Member | - |
Training of Judith Segall
| University of California, Berkeley | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| LINEAGE CELL THERAPEUTICS, INC. | Health Technology |
| ONCOCYTE CORPORATION | Health Technology |
| Private companies | 2 |
|---|---|
Asterias Biotherapeutics, Inc.
 Asterias Biotherapeutics, Inc. BiotechnologyHealth Technology Asterias Biotherapeutics, Inc. is a clinical-stage biotechnology company, which focuses on developing and commercializing novel therapies in the emerging fields of cell therapy and regenerative medicine. Its product candidates include AST-OPC1, trial for spinal cord injuries; AST-VAC1, a patient specific cancer immunotherapy focused on acute myeloid leukemia; and AST-VAC2, a non-patient-specific cancer immunotherapy for non-small cell lung cancer. The company was founded on September 24, 2012 and is headquartered in Fremont, CA. | Health Technology |
AgeX Therapeutics, Inc.
 AgeX Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology AgeX Therapeutics, Inc. operates as a biotechnology company, which engages in the development and commercialization of novel therapeutics targeting human aging and degenerative diseases. Its product pipeline includes AGEX-VASC1, AGEX-BAT1, and AGEX-iTR1547. The company was founded by Michael D. West in 2017 and is headquartered in Alameda, CA. | Health Technology |
- Stock Market
- Insiders
- Judith Segall